Warts Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 92 Published: March 31, 2022 Report Code: GMDGDHC22060IDB

Warts are skin growth that is caused by a virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

The Warts Drugs in Development market research report provides an in-depth analysis of the warts pipeline landscape. The report provides comprehensive information on the therapeutics under development for Warts, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for warts and features dormant and discontinued projects.

Warts Pipeline Drugs Market Targets

The targets of the warts pipeline drugs market are Bacterial Cell Membrane, Cyclin Dependent Kinase 9, Human Papillomavirus Major Capsid Protein L1, Integrin Alpha 4, Integrin Alpha V, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Interleukin 10, RNA, and Toll Like Receptor 7.

Warts Pipeline Drugs Market, By Targets

Warts Pipeline Drugs Market, By Targets

For more target insights, download a free report sample

Mechanisms of Action of Warts Pipeline Drugs Market

The mechanisms of action of the warts pipeline drugs market are Bacterial Cell Membrane Disruptor, Cyclin Dependent Kinase 9 Inhibitor, Integrin Alpha 4 Antagonist, Integrin Alpha V Antagonist, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, Interleukin 10 Inhibitor, RNA Synthesis Inhibitor, Toll Like Receptor 7 Agonist, and Tumor Necrosis Factor Receptor Superfamily Member 1A Agonist.

Warts Pipeline Drugs Market, By Mechanisms of Action

Warts Pipeline Drugs Market, By Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Routes of Administration in Warts Pipeline Drugs Market

The routes of administration in the warts pipeline drugs market are topical, intramuscular, cutaneous, parenteral, transdermal, vaginal, intravenous, ophthalmic, subcutaneous, and intradermal.

Warts Pipeline Drugs Market, By Routes of Administration

Warts Pipeline Drugs Market, By Routes of Administration

For more routes of administration insights, download a free report sample

Molecule Types in Warts Pipeline Drugs Market

The molecule types in the warts pipeline drugs market are small molecule, subunit vaccine, cell therapy, recombinant vector vaccine, vaccine, DNA vaccine, peptide, protein, recombinant enzyme, recombinant protein, and synthetic peptide.

Warts Pipeline Drugs Market, By Molecule Types

Warts Pipeline Drugs Market, By Molecule Types

For more molecule type insights, download a free report sample

Key Warts Pipeline Drugs Market Companies

Some of the key companies in the warts pipeline drugs market are KinoPharma Inc, Verrica Pharmaceuticals Inc, Novan Inc, Shanghai Bovax Biotechnology Co Ltd, Xiamen Innovax Biotech Co Ltd, Aclaris Therapeutics Inc, Beijing Kangle Guardian Biotechnology Co Ltd, Chengdu Institute of Biological Products Co Ltd, Cutanea Life Sciences Inc, and Cytovation AS.

Warts Pipeline Drugs Market, By Key Companies

Warts Pipeline Drugs Market, By Key Companies

To know more about key companies, download a free report sample

Market report overview

Targets Bacterial Cell Membrane, Cyclin Dependent Kinase 9, Human Papillomavirus Major Capsid Protein L1, Integrin Alpha 4, Integrin Alpha V, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Interleukin 10, RNA, and Toll Like Receptor 7
Mechanisms of Action Bacterial Cell Membrane Disruptor, Cyclin Dependent Kinase 9 Inhibitor, Integrin Alpha 4 Antagonist, Integrin Alpha V Antagonist, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, Interleukin 10 Inhibitor, RNA Synthesis Inhibitor, Toll Like Receptor 7 Agonist, and Tumor Necrosis Factor Receptor Superfamily Member 1A Agonist
Routes of Administration Topical, Intramuscular, Cutaneous, Parenteral, Transdermal, Vaginal, Intravenous, Ophthalmic, Subcutaneous, and Intradermal
Molecule Types Small Molecule, Subunit Vaccine, Cell Therapy, Recombinant Vector Vaccine, Vaccine, DNA Vaccine, Peptide, Protein, Recombinant Enzyme, Recombinant Protein, and Synthetic Peptide
Key Companies KinoPharma Inc, Verrica Pharmaceuticals Inc, Novan Inc, Shanghai Bovax Biotechnology Co Ltd, Xiamen Innovax Biotech Co Ltd, Aclaris Therapeutics Inc, Beijing Kangle Guardian Biotechnology Co Ltd, Chengdu Institute of Biological Products Co Ltd, Cutanea Life Sciences Inc, and Cytovation AS

Scope 

This report provides:

  • A snapshot of the global therapeutic landscape of warts (Infectious Disease).
  • Reviews of pipeline therapeutics for warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • Evaluation of Warts (Infectious Disease) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Warts (Infectious Disease).

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for warts (Infectious Disease). Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Key Players

  • Aclaris Therapeutics Inc

    Beijing Kangle Guardian Biotechnology Co Ltd

    Chengdu Institute of Biological Products Co Ltd

    Cutanea Life Sciences Inc

    Cytovation AS

    Douglas Pharmaceuticals Ltd

    Etna Biotech Srl

    Feramda Ltd

    G&E Herbal Biotechnology Co.

  • Ltd.

    Genetic Immunity Inc

    Guangzhou Cape Biological Technology Co Ltd

    Hefei Ruichengsheng Biotechnology Co Ltd

    KinoPharma Inc

    Laboratories Ojer Pharma SL

    Maruho Co Ltd

    Merck & Co Inc

    Nielsen Biosciences Inc

    Novan Inc

    Orgenesis Inc

    Peritech Pharma

    Phio Pharmaceuticals Corp

    Shanghai Bovax Biotechnology Co Ltd

    Shanghai Zerun Biotechnology Co Ltd

    SinoCelltech Group Ltd

    Veloce BioPharma LLC

    Verrica Pharmaceuticals Inc

    Xiamen Innovax Biotech Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Warts – Overview

Warts – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Warts – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Warts – Companies Involved in Therapeutics Development

Aclaris Therapeutics Inc

Beijing Kangle Guardian Biotechnology Co Ltd

Chengdu Institute of Biological Products Co Ltd

Cutanea Life Sciences Inc

Cytovation AS

Douglas Pharmaceuticals Ltd

Etna Biotech Srl

Feramda Ltd

G&E Herbal Biotechnology Co., Ltd.

Genetic Immunity Inc

Guangzhou Cape Biological Technology Co Ltd

Hefei Ruichengsheng Biotechnology Co Ltd

KinoPharma Inc

Laboratories Ojer Pharma SL

Maruho Co Ltd

Merck & Co Inc

Nielsen Biosciences Inc

Novan Inc

Orgenesis Inc

Peritech Pharma

Phio Pharmaceuticals Corp

Shanghai Bovax Biotechnology Co Ltd

Shanghai Zerun Biotechnology Co Ltd

SinoCelltech Group Ltd

Veloce BioPharma LLC

Verrica Pharmaceuticals Inc

Xiamen Innovax Biotech Co Ltd

Warts – Drug Profiles

(lopinavir + ritonavir) – Drug Profile

Product Description

Mechanism Of Action

Albicin – Drug Profile

Product Description

Mechanism Of Action

History of Events

AS-101 – Drug Profile

Product Description

Mechanism Of Action

History of Events

cantharidin – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cellular Immunotherapy for Condyloma – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cellular Immunotherapy for Human Papillomavirus Infections – Drug Profile

Product Description

Mechanism Of Action

chloroquine phosphate – Drug Profile

Product Description

Mechanism Of Action

CyPep-1 – Drug Profile

Product Description

Mechanism Of Action

FIT-039 – Drug Profile

Product Description

Mechanism Of Action

History of Events

human papillomavirus (9 valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

human papillomavirus (9 valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

human papillomavirus (9-valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

human papillomavirus [serotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58] (9-valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

human papillomavirus [serotypes 6, 11] (bivalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

human papillomavirus [serotypes 6, 11] (bivalent, virus like particle) vaccine – Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58,59 and 68] (11-valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58] (9-valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

human papillomavirus vaccine – Drug Profile

Product Description

Mechanism Of Action

human papillomavirus vaccine (tetravalent) – Drug Profile

Product Description

Mechanism Of Action

History of Events

HupaDerm – Drug Profile

Product Description

Mechanism Of Action

History of Events

hydrogen peroxide – Drug Profile

Product Description

Mechanism Of Action

History of Events

imiquimod SR – Drug Profile

Product Description

Mechanism Of Action

interferon alfa-2b – Drug Profile

Product Description

Mechanism Of Action

omiganan pentahydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

pefcalcitol – Drug Profile

Product Description

Mechanism Of Action

History of Events

PP-210 – Drug Profile

Product Description

Mechanism Of Action

ranpirnase – Drug Profile

Product Description

Mechanism Of Action

History of Events

RKP-00156 – Drug Profile

Product Description

Mechanism Of Action

Samcyprone – Drug Profile

Product Description

Mechanism Of Action

History of Events

SB-206 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SB-207 – Drug Profile

Product Description

Mechanism Of Action

SCT-1000 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Human Papillomavirus Infections – Drug Profile

Product Description

Mechanism Of Action

SRT-100 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VBP-245 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VP-103 – Drug Profile

Product Description

Mechanism Of Action

Warts – Dormant Projects

Warts – Discontinued Products

Warts – Product Development Milestones

Featured News & Press Releases

Jan 19, 2021: Verrica Pharmaceuticals presents positive data from clinical studies evaluating the safety and efficacy of VP-102 in molluscum and external genital warts at the 2021 Winter Clinical Dermatology Conference

Nov 10, 2020: Verrica Pharmaceuticals announces positive topline results in Phase 2 clinical study of VP-102 in patients with external genital warts (CARE-1)

Oct 24, 2019: Aclaris Therapeutics A-101 45% topical solution meets primary and all secondary efficacy endpoints in second successful pivotal phase 3 clinical trial for the treatment of common warts (THWART-1)

Oct 18, 2019: Novan further expands its proprietary nitric oxide platform

Oct 18, 2019: Verrica Pharmaceuticals announces presentation of positive data from clinical trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference

Sep 16, 2019: Aclaris Therapeutics A-101 45% Topical Solution meets primary and all secondary efficacy endpoints in pivotal phase 3 trial for the treatment of common warts (THWART-2)

Jul 24, 2019: Novan’s drug substance demonstrates inhibition of HPV-18 virus production

Jun 27, 2019: Verrica Pharmaceuticals enrolls first patient in Phase 2 trial of VP-102 for the treatment of external genital warts

Jun 26, 2019: Verrica Pharmaceuticals achieves positive topline results in phase 2 clinical study of VP-102 in [atients with common warts

Mar 18, 2019: Cytovation initiates clinical development programme with CyPep-1, a first-in-class lytic agent for tumor immunotherapy

Feb 19, 2019: Aclaris Therapeutics to present scientific posters at the 77th Annual Meeting of the American Academy of Dermatology

Nov 01, 2018: Novan Publication Supports Women’s Health Business Unit Initiative and Nitric Oxide’s Potential Against HPV-Associated Diseases

Sep 24, 2018: Aclaris Therapeutics Announces First Patient Dosed in Phase 3 Studies Evaluating A-101 45% in Patients with Common Warts

Jul 19, 2018: Cassiopea announces top line positive proof of concept phase II results for CB-06-02 immune modulator in treating genital warts

May 18, 2018: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone for the Treatment of Common Warts

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Warts, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Warts – Pipeline by Aclaris Therapeutics Inc, 2022

Warts – Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, 2022

Warts – Pipeline by Chengdu Institute of Biological Products Co Ltd, 2022

Warts – Pipeline by Cutanea Life Sciences Inc, 2022

Warts – Pipeline by Cytovation AS, 2022

Warts – Pipeline by Douglas Pharmaceuticals Ltd, 2022

Warts – Pipeline by Etna Biotech Srl, 2022

Warts – Pipeline by Feramda Ltd, 2022

Warts – Pipeline by G&E Herbal Biotechnology Co., Ltd., 2022

Warts – Pipeline by Genetic Immunity Inc, 2022

Warts – Pipeline by Guangzhou Cape Biological Technology Co Ltd, 2022

Warts – Pipeline by Hefei Ruichengsheng Biotechnology Co Ltd, 2022

Warts – Pipeline by KinoPharma Inc, 2022

Warts – Pipeline by Laboratories Ojer Pharma SL, 2022

Warts – Pipeline by Maruho Co Ltd, 2022

Warts – Pipeline by Merck & Co Inc, 2022

Warts – Pipeline by Nielsen Biosciences Inc, 2022

Warts – Pipeline by Novan Inc, 2022

Warts – Pipeline by Orgenesis Inc, 2022

Warts – Pipeline by Peritech Pharma, 2022

Warts – Pipeline by Phio Pharmaceuticals Corp, 2022

Warts – Pipeline by Shanghai Bovax Biotechnology Co Ltd, 2022

Warts – Pipeline by Shanghai Zerun Biotechnology Co Ltd, 2022

Warts – Pipeline by SinoCelltech Group Ltd, 2022

Warts – Pipeline by Veloce BioPharma LLC, 2022

Warts – Pipeline by Verrica Pharmaceuticals Inc, 2022

Warts – Pipeline by Xiamen Innovax Biotech Co Ltd, 2022

Warts – Dormant Projects, 2022

Warts – Dormant Projects, 2022 (Contd..1)

Warts – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Warts, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.